12/4
01:17 pm
imtx
Why Is Immatics N.V. (IMTX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Immatics N.V. (IMTX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
11/28
08:04 am
imtx
Immatics (NASDAQ: IMTX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Medium
Report
Immatics (NASDAQ: IMTX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
11/20
07:17 am
imtx
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Low
Report
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
11/19
12:46 pm
imtx
Immatics (NASDAQ: IMTX) had its price target lowered by analysts at Bank of America Co. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Immatics (NASDAQ: IMTX) had its price target lowered by analysts at Bank of America Co. from $16.00 to $15.00. They now have a "buy" rating on the stock.
11/18
01:40 pm
imtx
What Makes Immatics (IMTX) a New Buy Stock [Yahoo! Finance]
Medium
Report
What Makes Immatics (IMTX) a New Buy Stock [Yahoo! Finance]
11/18
07:12 am
imtx
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME [Yahoo! Finance]
Medium
Report
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME [Yahoo! Finance]
11/18
07:00 am
imtx
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Medium
Report
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
11/8
05:00 pm
imtx
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Low
Report
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
11/5
12:13 pm
imtx
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Low
Report
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
10/23
07:21 am
imtx
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% [Yahoo! Finance]
Low
Report
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% [Yahoo! Finance]
10/10
08:50 pm
imtx
Immatics Announces Pricing of $150 Million Public Offering
Low
Report
Immatics Announces Pricing of $150 Million Public Offering
10/10
07:30 am
imtx
Immatics Announces Proposed $150 Million Public Offering
High
Report
Immatics Announces Proposed $150 Million Public Offering
10/10
06:30 am
imtx
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
High
Report
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
10/7
08:10 am
imtx
Immatics (NASDAQ: IMTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $19.00 price target on the stock.
Low
Report
Immatics (NASDAQ: IMTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $19.00 price target on the stock.
10/4
09:00 am
imtx
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Low
Report
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024